Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Eye Diseases Disproportionately Common in Cushing’s, Study Finds

Rates of eye-related disorders called pachychoroid spectrum diseases are higher among people with Cushing’s syndrome than in the general population, a recent study reported. “We find that patients with Cushing’s syndrome have a high prevalence of any pachychoroid spectrum disease. Thus, in patients with Cushing’s syndrome there should be generally…

Bleeding in Pituitary May Complicate Diagnosis of Cushing’s Disease

Children and adolescents with Cushing’s disease who have subclinical bleeding near their disease-driving tumors may respond differently to tests used to diagnose the disease, compared with patients without this bleeding, according to a new study. These differences may complicate the diagnostic workup of these patients and “should be incorporated…

New Data Support Long-term Efficacy, Safety of Isturisa

Treatment with Isturisa (osilodrostat) normalized urine cortisol levels up to nearly 1.5 years in people with Cushing’s disease, according to data from the Phase 3 LINC-4 clinical trial. Data from another Phase 3 trial, LINC-3 (NCT02180217), showed that testosterone levels were generally stable among Cushing’s patients treated with…

Recorlev Helps to Keep Cholesterol in Check, LOGICS Trial Data Show

Continuous treatment with Recorlev (levoketoconazole) helped to lower blood cholesterol levels in adults with endogenous Cushing’s syndrome, according to data from the Phase 3 LOGICS trial. Scientists at Xeris Biopharma, the company that markets Recorlev, presented the findings in the poster “Levoketoconazole in the Treatment of Endogenous…